Celldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria

Celldex Therapeutics (CLDX) announced positive Phase 2 trial results for barzolvolimab in chronic spontaneous urticaria (CSU), showing significant angioedema symptom reduction; 77% of patients treated with 150mg every four weeks were angioedema-free at week 52, with an 86% average reduction in angioedema activity scores. These results build on earlier data demonstrating a strong therapeutic effect at 12 weeks, supporting barzolvolimab's potential to redefine CSU treatment. The company is currently conducting Phase 3 trials to further validate efficacy and safety in severe CSU patients unresponsive to existing treatments, though the release contains a cautionary note regarding forward-looking statements.

Analysis

Celldex Therapeutics (CLDX) reported compelling 52-week Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU), demonstrating significant clinical efficacy. Specifically, 77% of patients with baseline angioedema treated with 150 mg every four weeks were angioedema-free at week 52, accompanied by an average 86% reduction in angioedema activity scores (AAS7). These long-term results build upon previously announced positive 12-week primary and secondary endpoint data, including statistically significant decreases in weekly urticaria activity score (UAS7) and improvements in quality of life. Barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor on mast cells, is now advancing into global Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) for CSU, including patients unresponsive to current biologics, signaling a clear path towards potential regulatory submission. The drug is also under investigation for other mast cell-mediated conditions like chronic inducible urticaria and atopic dermatitis. While the efficacy data is strong, the press release lacks detailed safety and adverse event information, and its focus on patients with angioedema at baseline may not fully represent the broader CSU population. Institutional holdings data from the most recent quarter reveals mixed sentiment, with 87 firms adding shares and 114 decreasing positions; notable activity includes Commodore Capital LP initiating a significant $58 million position and Kynam Capital Management LP adding $26 million, while Jefferies Financial Group Inc. and T. Rowe Price Investment Management, Inc. substantially reduced or exited their holdings. Analyst sentiment remains positive, with Morgan Stanley and Citigroup issuing "Overweight" and "Buy" ratings respectively in early 2025, and no sell ratings recorded.

Key Decisions for Investors

• Investors should view the strong 52-week Phase 2 efficacy data for barzolvolimab as a significant de-risking event for Celldex's lead asset, warranting close attention to the progress and comprehensive data from the ongoing Phase 3 trials, particularly regarding the full safety profile and efficacy across broader CSU patient segments.